Myriad and Bayer expand proteomics deal

MYGN and Bayer (DAX:BAYG) extended and expanded their 1997 collaboration to develop products to treat dementia using MYGN's ProNet proteomics technology (see BioCentury, Nov. 24, 1997). The collaborat...